Status:
UNKNOWN
SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
Lead Sponsor:
Clinical Alliance for Research & Education - Infectious Diseases, LLC.
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
HIV Infections
Lipodystrophy
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
SHARE: Simple HAART with Abacavir, Reyataz, and Epivir
Detailed Description
Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA \<50 copies/mL at ...
Eligibility Criteria
Inclusion
- Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen
- Viral load \<50 copies/ml
Exclusion
- Viral load \>50 copies/ml
- Having taken more than one antiretroviral regimen
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00426296
Start Date
August 1 2006
Last Update
November 1 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Whitman-Walker Clinic
Washington D.C., District of Columbia, United States